Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $266.26 billion
- Book Value:
- Revenue TTM:
- $58.05 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $41.53 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
AbbVie Inc had its IPO on 2013-01-02 under the ticker symbol ABBV.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. AbbVie Inc has a staff strength of 50,000 employees.
Shares of AbbVie Inc opened at $133.71 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $133.5 - $136.97, and closed at $136.87.
This is a +2.57% increase from the previous day's closing price.
A total volume of 6,660,505 shares were traded at the close of the day’s session.
In the last one week, shares of AbbVie Inc have slipped by -3.03%.
AbbVie Inc's Key Ratios
AbbVie Inc has a market cap of $266.26 billion, indicating a price to book ratio of 18.2288 and a price to sales ratio of 4.9887.
In the last 12-months AbbVie Inc’s revenue was $58.05 billion with a gross profit of $41.53 billion and an EBITDA of $31.09 billion. The EBITDA ratio measures AbbVie Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AbbVie Inc’s operating margin was 38.97% while its return on assets stood at 9.91% with a return of equity of 72.39%.
In Q4, AbbVie Inc’s quarterly earnings growth was a negative -38.8% while revenue growth was a positive 1.6%.
AbbVie Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $6.63 per share while it has a forward price to earnings multiple of 14.3885 and a PEG multiple of 1.2788. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AbbVie Inc’s profitability.
AbbVie Inc stock is trading at a EV to sales ratio of 6.0409 and a EV to EBITDA ratio of 13.7968. Its price to sales ratio in the trailing 12-months stood at 4.9887.
AbbVie Inc stock pays annual dividends of $5.71 per share, indicating a yield of 3.81% and a payout ratio of 41.41%.
Balance sheet and cash flow metrics
- Total Assets
- $138.81 billion
- Total Liabilities
- $29.54 billion
- Operating Cash Flow
- Capital Expenditure
- $213 million
- Dividend Payout Ratio
AbbVie Inc ended 2023 with $138.81 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $138.81 billion while shareholder equity stood at $17.25 billion.
AbbVie Inc ended 2023 with $2.19 billion in deferred long-term liabilities, $29.54 billion in other current liabilities, 18000000.00 in common stock, $4.78 billion in retained earnings and $32.16 billion in goodwill. Its cash balance stood at $9.20 billion and cash and short-term investments were $9.23 billion. The company’s total short-term debt was $4,136,000,000 while long-term debt stood at $59.14 billion.
AbbVie Inc’s total current assets stands at $28.46 billion while long-term investments were $241.00 million and short-term investments were $28.00 million. Its net receivables were $11.25 billion compared to accounts payable of $25.40 billion and inventory worth $3.58 billion.
In 2023, AbbVie Inc's operating cash flow was $-448000000.00 while its capital expenditure stood at $213 million.
Comparatively, AbbVie Inc paid $0.41 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
AbbVie Inc stock is currently trading at $136.87 per share. It touched a 52-week high of $169.4595 and a 52-week low of $169.4595. Analysts tracking the stock have a 12-month average target price of $163.22.
Its 50-day moving average was $151.77 and 200-day moving average was $148.49 The short ratio stood at 1.87 indicating a short percent outstanding of 0%.
Around 11.8% of the company’s stock are held by insiders while 7152.7% are held by institutions.
Frequently Asked Questions About AbbVie Inc
Similar Industry Stocks (Drug Manufacturers-General)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson’s disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.